Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors
Changchun High‑Tech (SHE: 000661) announced today that its wholly‑owned subsidiary, GenSci (GeneScience Pharmaceutical), has received...
Drug
Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced today that its U.S. subsidiary, Salubris Biotherapeutics,...
Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC
Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it...
Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...
CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer
CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...
CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...
Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC
Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...
Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...
Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer
Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...
Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC
Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...
Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer
Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...
Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...
Huadong Medicine Secures NMPA Approval for Relmapirazin Injection, Complementing MediBeacon TGFR Device
Huadong Medicine (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has granted marketing...
CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC
CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal...
Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...
Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy
Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...
Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC
Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...
HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI
HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...
Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...
Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC
Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase 3 HER2CLIMB‑05 trial, evaluating...